Clinical application progress of circulating tumor cells for accurate dynamic monitoring of hepatocellular carcinoma

Abstract

Abstract: Hepatocellular carcinoma (HCC) is the fifth most common neoplasm and a major cause of cancer-related death worldwide. There is no ideal biomarker allowing early diagnosis of HCC and tumor surveillance in patients receiving therapy. Circulating tumor cells (CTC) have become a useful tool for diagnosing and monitoring therapeutic responses of different tumors in a non-invasive setting, and have great potential for precision medicine delivery in HCC patients. Based on existing clinical application evidence, this review will discuss the application and research progress of CTC in guiding surgical methods, resection margins, interventional therapy and systematic therapy, and other accurate dynamic monitoring.

Key words: Hepatocellular carcinoma, Circulating tumor cell, Microvascular invasion, Anatomical resection, Non-anatomical resection

Huang Xiaozhun, Wang Fuzun, Xie Yunliang, Ran Yihong, Xu Lin, Huang Zhangkan, Yin Xin, Bi Xinyu, Che Xu. Clinical application progress of circulating tumor cells for accurate dynamic monitoring of hepatocellular carcinoma[J]. Electronic Journal of Liver Tumor, 2024, 11(1): 21-24.

References

[1] FERLAY J, SOERJOMATARAM I, DIKSHIT R, et al.Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5): E359-E386.
[2] BRUIX J, SHERMAN M.Management of hepatocellular carcinoma: an update[J]. Hepatology, 2011, 53(3): 1020-1022.
[3] TABRIZIAN P, JIBARA G, SHRAGER B, et al.Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis[J]. Ann Surg, 2015, 261(5): 947-955.
[4] YE Q, LING S, ZHENG S, et al.Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA[J]. Mol Cancer, 2019, 18(1): 114.
[5] SUN Y F, GUO W, XU Y, et al.Circulating Tumor Cells from Different Vascular Sites Exhibit Spatial Heterogeneity in Epithelial and Mesenchymal Composition and Distinct Clinical Significance in Hepatocellular Carcinoma[J]. Clin Cancer Res, 2018, 24(3): 547-559.
[6] LEE H M, JOH J W, SEO S R, et al.Cell-surface major vault protein promotes cancer progression through harboring mesenchymal and intermediate circulating tumor cells in hepatocellular carcinomas[J]. Sci Rep, 2017, 7(1): 13201.
[7] SUO Y, XIE C, ZHU X, et al.Proportion of circulating tumor cell clusters increases during cancer metastasis[J]. Cytometry A, 2017, 91(3): 250-253.
[8] RODRíGUEZ-PERáLVAREZ M, LUONG T V, ANDREANA L, et al. A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variability[J]. Ann Surg Oncol, 2013, 20(1): 325-339.
[9] JOHNSON P J.The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma[J]. Clin Liver Dis, 2001, 5(1): 145-159.
[10] ÖZDEMIR F, BASKIRAN A.The Importance of AFP in Liver Transplantation for HCC[J]. J Gastrointest Cancer, 20YAMASHITA Y, TSUIJITA E, TAKEISHI K, et al. Predictors for microinvasion of small hepatocellular carcinoma ≤2 cm[J]. Ann Surg Oncol, 2012, 19(6): 2027-2034.
[11] SHIRABE K, TOSHIMA T, KIMURA K, et al.New scoring system for prediction of microvascular invasion in patients with hepatocellular carcinoma[J]. Liver Int, 2014, 34(6): 937-941.
[12] RENZULLI M, BROCCHI S, CUCCHETTI A, et al.Can Current Preoperative Imaging Be Used to Detect Microvascular Invasion of Hepatocellular Carcinoma?[J]. Radiology, 2016, 279(2): 432-442.
[13] POTé N, CAUCHY F, ALBUQUERQUE M, et al.Performance of PIVKA-Ⅱ for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion[J]. J Hepatol, 2015, 62(4): 848-854.
[14] YAMASHITA Y I, IMAI K, YUSA T, et al.Microvascular invasion of single small hepatocellular carcinoma ≤3 cm: Predictors and optimal treatments[J]. Ann Gastroenterol Surg, 2018, 2(3): 197-203.
[15] DU M, CHEN L, ZHAO J, et al.Microvascular invasion (MVI) is a poorer prognostic predictor for small hepatocellular carcinoma[J]. BMC Cancer, 2014, 14: 38.
[16] ZHOU J, WANG Z, QIU S J, et al.Surgical treatment for early hepatocellular carcinoma: comparison of resection and liver transplantation[J]. J Cancer Res Clin Oncol, 2010, 136(9): 1453-1460.
[17] YAMANAKA N, OKAMOTO E, FUJIHARA S, et al.Do the tumor cells of hepatocellular carcinomas dislodge into the portal venous stream during hepatic resection?[J]. Cancer, 1992, 70(9): 2263-2267.
[18] YU J J, XIAO W, DONG S L, et al.Effect of surgical liver resection on circulating tumor cells in patients with hepatocellular carcinoma[J]. BMC Cancer, 2018, 18(1): 835.
[19] HA Y, KIM T H, SHIM J E, et al.Circulating tumor cells are associated with poor outcomes in early-stage hepatocellular carcinoma: a prospective study[J]. Hepatol Int, 2019, 13(6): 726-735.
[20] SUN Y F, XU Y, YANG X R, et al.Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection[J]. Hepatology, 2013, 57(4): 1458-1468.
[21] CHEN Z, LIN X, CHEN C, et al.Analysis of preoperative circulating tumor cells for recurrence in patients with hepatocellular carcinoma after liver transplantation[J]. Ann Transl Med, 2020, 8(17): 1067.
[22] SUN Y F, WANG P X, CHENG J W, et al.Postoperative circulating tumor cells: An early predictor of extrahepatic metastases in patients with hepatocellular carcinoma undergoing curative surgical resection[J]. Cancer Cytopathol, 2020, 128(10): 733-745.
[23] ZHOU K Q, SUN Y F, CHENG J W, et al.Effect of surgical margin on recurrence based on preoperative circulating tumor cell status in hepatocellular carcinoma[J]. EBioMedicine, 2020, 62: 103107.
[24] YU JJ, SHU C, YANG H Y, et al.The Presence of Circulating Tumor Cell Cluster Characterizes an Aggressive Hepatocellular Carcinoma Subtype[J]. Front Oncol, 2021, 11: 734564.
[25] FAN J L, YANG Y F, YUAN C H, et al.Circulating Tumor Cells for Predicting the Prognostic of Patients with Hepatocellular Carcinoma: A Meta Analysis[J]. Cell Physiol Biochem, 2015, 37(2): 629-640.
[26] SHEN J, WANG W S, ZHU X L, et al.High Epithelial Cell Adhesion Molecule-Positive Circulating Tumor Cell Count Predicts Poor Survival of Patients with Unresectable Hepatocellular Carcinoma Treated with Transcatheter Arterial Chemoembolization[J]. J Vasc Interv Radiol, 2018, 29(12): 1678-1684.
[27] HE Y Z, HE K, HUANG R Q, et al.A clinical scoring system for predicting tumor recurrence after percutaneous radiofrequency ablation for 3 cm or less hepatocellular carcinoma[J]. Sci Rep, 2021, 11(1): 8275.
[28] ZHANG Q, XIA F, GAO H, et al.Circulating Tumor Cells as an Indicator of Treatment Options for Hepatocellular Carcinoma Less Than or Equal to 3 cm in Size: A Multi-Center, Retrospective Study[J]. Front Surg, 2022, 9: 895426.
[29] CHEN Z, WANG T, CHEN C, et al.Circulating Tumor Cell Is a Clinical Indicator of Pretransplant Radiofrequency Ablation for Patients with Hepatocellular Carcinoma[J]. J Oncol, 2021: 7776389.
[30] HUANG X, XU L, MA T, et al.Lenvatinib Plus Immune Checkpoint Inhibitors Improve Survival in Advanced Hepatocellular Carcinoma: A Retrospective Study[J]. Front Oncol, 2021, 11: 751159.
[31] RAU K M, LIU C T, HSIAO Y C, et al.Sequential Circulating Tumor Cell Counts in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: Monitoring the Treatment Response[J]. J Clin Med, 2020, 9(1): 188.
[32] TELLEZ-GABRIEL M, COCHONNEAU D, CADé M, et al.Circulating Tumor Cell-Derived Pre-Clinical Models for Personalized Medicine[J]. Cancers (Basel), 2018, 11(1): 19.
[33] KLAMETH L, RATH B, HOCHMAIER M, et al.Small cell lung cancer: model of circulating tumor cell tumorospheres in chemoresistance[J]. Sci Rep, 2017, 7(1): 5337.
[34] HU C L, ZHANG Y J, ZHANG X F, et al.3D Culture of Circulating Tumor Cells for Evaluating Early Recurrence and Metastasis in Patients with Hepatocellular Carcinoma[J]. Onco Targets Ther, 2021, 14: 2673-2688.
[35] ZHANG Y, ZHANG X, ZHANG J, et al.Microfluidic chip for isolation of viable circulating tumor cells of hepatocellular carcinoma for their culture and drug sensitivity assay[J]. Cancer Biol Ther, 2016, 17(11): 1177-1187.
[36] PAILLER E, FAUGEROUX V, OULHEN M, et al.Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK-Rearranged Non-Small-Cell Lung Cancer[J]. Clin Cancer Res, 2019, 25(22): 6671-6682.
[37] LOHR J G, KIM S, GOULD J, et al. Genetic interrogation of circulating multiple myeloma cells at single-cell resolution[J]. Sci Transl Med, 2016, 8(363): 363ra147.
[38] D'AVOLA D, VILLACORTA-MARTIN C, MARTINS-FILHO S N, et al. High-density single cell mRNA sequencing to characterize circulating tumor cells in hepatocellular carcinoma[J]. Sci Rep, 2018, 8(1): 11570.